<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01016743</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-09-7279-OC-CTIL</org_study_id>
    <nct_id>NCT01016743</nct_id>
  </id_info>
  <brief_title>The Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effects of low frequency deep rTMS using the novel H-coil on the motor, affective&#xD;
      and cognitive deficits in patients with asymmetric Parkinson's disease (PD) and to establish&#xD;
      its safety in this population. The investigators anticipate that reaching deeper brain layers&#xD;
      and larger volume of activation with the novel H-coil may induce significantly better&#xD;
      therapeutic effects in patients with PD and will pave the way for establishing a novel and&#xD;
      effective treatment for this disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PD patients with asymmetric disease aged 40 years or older, diagnosed as idiopathic PD&#xD;
      according to the UK Brain Bank criteria, with Hoehn &amp; Yahr stages II - IV while &quot;off&quot; will be&#xD;
      recruited. Participants on antidepressants should be at least 2 months on stable therapy.&#xD;
&#xD;
      Patient will be excluded if:&#xD;
&#xD;
        1. They have concomitant epilepsy, a history of seizure or heat convulsion or history of&#xD;
           epilepsy in first degree relative.&#xD;
&#xD;
        2. Are on neuroleptics.&#xD;
&#xD;
        3. Have dementia or any unstable medical disorder.&#xD;
&#xD;
        4. Have a history or current unstable hypertension.&#xD;
&#xD;
        5. Have a history of head injury or neurosurgical interventions.&#xD;
&#xD;
        6. Have a history of any metal in the head (outside the mouth).&#xD;
&#xD;
        7. Have a known history of any metallic particles in the eye, implanted cardiac pacemaker,&#xD;
           implanted neurostimulators, surgical clips (above the shoulder line) or any medical&#xD;
           pumps.&#xD;
&#xD;
      Patients will be randomized into two groups: The first group of patients will receive an&#xD;
      active unilateral stimulation over the motor cortex contralateral to the more affected body&#xD;
      side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will&#xD;
      receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal&#xD;
      cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for&#xD;
      15 minutes).&#xD;
&#xD;
      The following outcome measures will be taken prior to the treatment (screening visit), and at&#xD;
      day 1, 10, 30 and 60 Evaluation will be while subjects both at &quot;on&quot; and &quot;off&quot;.&#xD;
&#xD;
      Motor:&#xD;
&#xD;
        1. Unified Parkinson's Disease Rating Scale (UPDRS )&#xD;
&#xD;
        2. Clinical Global Impression of Severity (CGIS)&#xD;
&#xD;
        3. Pegboard test.&#xD;
&#xD;
        4. Tapping test&#xD;
&#xD;
        5. Up &amp; Go test&#xD;
&#xD;
        6. Abnormal Involuntary Movement Scale (AIMS) Mood and affect&#xD;
&#xD;
      1. Beck Depression Inventory (BDI) Cognition&#xD;
&#xD;
        1. Mini mental State examination (MMSE)&#xD;
&#xD;
        2. Digit forward and backward tests.&#xD;
&#xD;
        3. Word fluency.&#xD;
&#xD;
        4. Frontal Assessment Battery (FAB) Side effects will be closely monitored by the&#xD;
           researchers and will be promptly reported to the IRB.&#xD;
&#xD;
      8.Have a history of migraine or frequent or severe headaches. 9.Have a history of hearing&#xD;
      loss. 10.Has a of cochlear implants 11.Have a history of drug abuse or alcoholism. 12.Is&#xD;
      pregnant or not using a reliable method of birth control. 13.Is participating in current&#xD;
      clinical study or clinical study within 30 days prior to this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS )</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGIS,Pegboard test.Tapping test,Up&amp;Go test,AIMS,BDI,MMSE,Word fluencyFAB</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>UPDRS</condition>
  <arm_group>
    <arm_group_label>Active repetitive transcranial Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive transcranial stimulation (r-TMS)</intervention_name>
    <description>Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).</description>
    <arm_group_label>Active repetitive transcranial Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PD patients with asymmetric disease aged 40 years or older, diagnosed as idiopathic PD&#xD;
             according to the UK Brain Bank criteria, with Hoehn &amp; Yahr stages II - IV while &quot;off&quot;.&#xD;
&#xD;
          -  Participants on antidepressants should be at least 2 months on stable therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have concomitant epilepsy, a history of seizure or heat convulsion or&#xD;
             history of epilepsy in first degree relative.&#xD;
&#xD;
          -  Patients on neuroleptics.&#xD;
&#xD;
          -  Patients with dementia or any unstable medical disorder.&#xD;
&#xD;
          -  History or current unstable hypertension.&#xD;
&#xD;
          -  History of head injury or neurosurgical interventions.&#xD;
&#xD;
          -  History of any metal in the head (outside the mouth).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 18, 2009</study_first_submitted>
  <study_first_submitted_qc>November 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2009</study_first_posted>
  <last_update_submitted>November 18, 2009</last_update_submitted>
  <last_update_submitted_qc>November 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sheba Medical Center: Dr. Oren Cohen PI</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>parkinson</keyword>
  <keyword>rTMS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

